908 Devices upgraded to Outperform at Leerink on OBBA upside

As previously reported, Leerink upgraded 908 Devices (MASS) to Outperform from Market Perform with a price target of $12, up from $7. After the recent life science divestiture, 908 has “turned into a forensics and threat detection pure-play,” says the analyst, who notes that the One Big Beautiful Act releases funds for enforcement, security, drug and broader threat detection. 908 is guiding to 15% pro-forma growth for the year, but expecting an acceleration in 2026, notes the analyst, who sees upside to the company’s 20%-plus growth expectation for 2026.